StockpollyBeta
Get App
Popularity #3,890
FBIO · NASDAQ · Biotechnology

Fortress Biotech (FBIO)

Sources, funds and advances drug assets through a portfolio-company network.

$2.44
vs last close+0.02 (+1.04%)

  1. Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

    GlobeNewsWire

  2. Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript

    Seeking Alpha

  3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

    PRNewsWire

  4. Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

    GlobeNewsWire

  5. Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy

    Seeking Alpha

  6. Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?

    Seeking Alpha

  7. Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

    GlobeNewsWire

  8. Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    GlobeNewsWire

  9. Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

    GlobeNewsWire

  10. Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

    GlobeNewsWire

  11. Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

    GlobeNewsWire

  12. Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

    Defense World

  13. UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    GlobeNewsWire

  14. Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    GlobeNewsWire

  15. Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

    Seeking Alpha

  16. Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened

    Defense World

  17. Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average – What’s Next?

    Defense World

  18. Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

    GlobeNewsWire

  19. Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

    GlobeNewsWire

  20. Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

    Zacks Investment Research